Breast Cancer Genes
Anne M. Bowcock Ph.D.,
Corresponding Author
Anne M. Bowcock Ph.D.
Department of Pediatrics, McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Texas
Address correspondence and reprint requests to: Anne M. Bowcock, Department of Pediatrics, McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8591, U.S.A.Search for more papers by this authorAnne M. Bowcock Ph.D.,
Corresponding Author
Anne M. Bowcock Ph.D.
Department of Pediatrics, McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Texas
Address correspondence and reprint requests to: Anne M. Bowcock, Department of Pediatrics, McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8591, U.S.A.Search for more papers by this authorAbstract
Abstract: The identification of familial breast cancer genes heralds an era of directed breast cancer treatment. Currently, two hereditary breast cancer genes have been identified, BRCA-1 and BRCA-2. Although accounting for only approximately 5% of all breast cancers, they are being used to identify women with germ-line alterations that are at high risk of developing breast or ovarian cancer. With the identification of such genes comes a need for consideration of the ethical issues associated with testing. These genes are also being examined from a biochemical standpoint encompassing both their biological roles and biochemical pathways in which they reside. Such studies are likely to lead to novel breast cancer therapies.
REFERENCES
- 1 Hall JM, Lee MK, Newman B, et al. Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684–89.
- 2 Narod SA, Feunteun J, Lynch HT, Watson P, et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338: 82–83.
- 3 Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678–701.
- 4 Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56: 254–64.
- 5 Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996; 334: 137–42.
- 6 FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334: 143–49.
- 7 Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.
- 8 Couch FJ, Weber BL, And the Breast Cancer Information Core. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Human Mutation 1996; 8: 8–18.
- 9 Koonin EV, Altschul SF, Bork P. BRCA1 protein products: functional motifs. Nature Genet 1996; 13: 266–67.
- 10 Wu LC, Wang ZW, Tsan JT, et al. Identification of a RING protein that interacts in vivo with the BRCA1 gene product. Nature Genet 1996; 14: 430–40.
- 11 Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 1995; 273: 535–41.
- 12 Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2 to chromosome 13q12–13. Science 1994; 265: 2088–90.
- 13 Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378– 789–92.
- 14 Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Molec Genet 1996; 5: 1515–19.
- 15 Bork P, Blomberg N, Nilges M. Internal repeats in the BRCA2 protein sequence. Nature Genet 1996; 13: 22–23.
- 16 Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 1996; 12: 333–37.
- 17 Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genet 1996; 13: 123–25.
- 18 Phelan C, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 1996; 13: 120–22.
- 19 Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 1995; 11: 198–200.
- 20 Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996; 347: 1643–44.
- 21 Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet 1996; 13: 126–28.
- 22 Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet 1996; 14: 185–87.
- 23 Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1. Nature Genet 1996; 14: 188–90.
- 24 Orita M, Suzuki Y, Sekiya T. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874–79.
- 25 Orita M, Wahana H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-stranded conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766–70.
- 26 Roest P, Roberts R, Sugino S, et al. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Molec Genet 1993; 2: 1719–21.
- 27 Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet 1995; 11: 428–33.
- 28 Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 1995; 9: 439–43.
- 29 Hosking L, Trowsdale J, Nicolai H, et al. A somatic BRCA1 mutation in an ovarian tumour (letter). Nature Genet 1995; 9: 343–44.
- 30 Weber BHF, Brohm M, Stec I, et al. A somatic truncating mutation in BRCA2 in a sporadic breast tumor. Am J Hum Genet 1996; 59: 962–64.
- 31 Lancaster J, Wooster R, Mangion J, et al. BRCA1 mutations in primary breast and ovarian cancers. Nature Genet 1996; 13: 238–40.
- 32 Miki Y, Katagiri T, Kasumi F, et al. Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet 1996; 13: 245–47.
- 33 Thompson ME, Jensen RA, Obermiller PS, et al. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet 1995; 9: 444–50.
- 34 Marquis ST, Rajan JV, Wynshaw-Boris A, et al. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nature Genet 1995; 11: 17–26.
- 35 Spillman MA, Bowcock AM. Estrogen stimulation of the BT-483 breast cancer cell line results in increased levels of BRCA1 and ETV4 mRNAs. Am J Hum Genet 1995; 69 (Suppl): A5.
- 36 Gudas JM, Nguyen H, Li T. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995; 55: 4561–65.
- 37 Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 1996; 13: 1639–45.
